MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Mon Jun 23 00:00:00 GMT-05:00 2025
NEW
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Download
Wed Jun 18 00:00:00 GMT-05:00 2025
NEW
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
Download
Mon Jun 09 00:00:00 GMT-05:00 2025
NEW
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
Download
Mon Jun 02 00:00:00 GMT-05:00 2025
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial
Download
Sun Jun 01 00:00:00 GMT-05:00 2025
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
Download
Sat May 31 00:00:00 GMT-05:00 2025
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial
Download
Thu May 29 00:00:00 GMT-05:00 2025
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
Download
Thu May 22 00:00:00 GMT-05:00 2025
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
Download
Mon May 19 00:00:00 GMT-05:00 2025
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Download